Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 643 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma EMA Recommends Extending Indications for Lisocabtagene Maraleucel Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over... MOST POPULAR Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... January 24, 2022 Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... February 21, 2023 Cancer in My Community: How People With Cancer Access Care in... August 12, 2021 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 Load more HOT NEWS Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... Girl Whose Insides Were Sucked From Her Body While Sitting On... Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer...
